Immunicum has carried out a primary issuance of shares of approximately SEK 141.2 million at a subscription price of SEK 4.25 per share. The subscription price was determined through an accelerated book-building procedure.

Immunicum, based in Sweden and the Netherlands, is leveraging its expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients.

Carnegie and Kempen & Co acted as Joint Global Coordinators and Joint Bookrunners. Baker McKenzie acted as legal adviser to the Joint Global Coordinators and Joint Bookrunners with an international capital markets team consisting of Joakim Falkner and Johanna Flink from Stockholm as well as Adam Farlow and Charles Farnsworth from London.

Explore Our Newsroom